TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00400400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: Enteric-coated mycophenolate sodium supplied as 180 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil supplied as 250 mg capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to mycophenolate sodium
Description: Placebo to mycophenolate sodium matching tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mycophenolate mofetil
Description: Placebo to mycophenolate mofetil matching capsules.
Study: NCT02685917

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture without Collagen Augmentation
Description: Cartifill applied for collagen augmentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture with Collagen Augmentation
Description: Cartifill applied for collagen augmentation
Study: NCT00983411

Intervention type: OTHER
Intervention: Non intentional leaks during non invasive ventilation
Description: During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
Study: NCT00964431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400 mg
Description: Capsules 2 x 200 mg Single-Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules 2 Single-Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Test (lower dose)
Description: 20-mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Test (upper dose)
Description: 40-mg single dose
Study: NCT00003665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell-MART-1 peptide vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic tumor infiltrating lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic tumor infiltrating lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic tumor infiltrating lymphocytes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Study: NCT01911520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: Patients receive 2 mg/kg Sugammadex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex. 4 mg/kg
Description: Patients receive 4 mg/kg Sugammadex.
Study: NCT06217549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone therapy
Description: Medical ozone is a mixture of pure ozone gas (0.05-5%) and pure oxygen (99.95-95%). It is produced from pure medical oxygen by medical ozone generators. It is applied to the participants 10 sessions by the intravenous method.
Study: NCT01709344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PS-OT
Study: NCT02574104

Intervention type: OTHER
Intervention: Simulate a functional NICU prior to moving patients
Description: Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
Study: NCT01709344

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Supportive and rehabilitation services available at DHMC
Study: NCT04281199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: Undergo IMRT with tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Undergo IMRT with VMAT
Study: NCT04305015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOL Guided Analgesia
Description: NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine opioid management
Description: Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
Study: NCT01308411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% step down reduction in inhaled corticosteroid dose
Description: All participants will have their inhaled corticosteroid dose reduced by 50%
Study: NCT02224131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and clopidogrel
Description: modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel
Description: modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and clopidogrel
Description: aspirin and clopidogrel maintenance doses (according to international guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel
Description: aspirin and clopidogrel maintenance doses (according to international guidelines)
Study: NCT04642846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Description: Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Description: Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment
Study: NCT01320605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Weekly wound spray with components 1 and 2 of the compound HP802-247
Description: Weekly spray with HP802-247
Study: NCT01724437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter based pulmonary vein isolation
Description: catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter based pulmonary vein isolation
Description: catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
Study: NCT00660894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinate calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegafur-uracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-gimeracil-oteracil potassium
Study: NCT03229720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nibiru 3D Virtual Reality Headset
Description: This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
Study: NCT03142698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantification of hepatic steatosis
Description: Quantification of hepatic steatosis (histology, and in MRI)
Study: NCT03281785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled mandatory ventilation mode (P-CMV)
Description: Pressure controlled mandatory ventilation mode (P-CMV)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure synchronized intermittent mandatory ventilation
Description: Pressure synchronized intermittent mandatory ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure support mode (PS)
Description: Pressure support mode (PS)
Study: NCT02338687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational sessions
Description: Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational sessions
Description: Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
Study: NCT00716469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS11
Description: LS11 will be given as a one-time IV infusion over 3-5 minutes.
Study: NCT01535079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 35 mg
Description: Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 25 mg
Description: Single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 15 mg
Description: Single administration

Intervention type: DRUG
Group type: OTHER
Intervention: Strefen
Description: Single administration
Study: NCT06419283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle Cerebral Artery Stent Implantation
Description: Middle Cerebral Artery Stent Implantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment with aspirin.
Description: standard treatment with aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard treatment with aspirin.
Description: standard treatment with aspirin.
Study: NCT00506857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 by vein daily x 4 days.
Study: NCT01016873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system
Study: NCT03931304

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
Description: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
Study: NCT02909894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged Sitting
Description: Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light arm ergometry breaks
Description: Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
Study: NCT03501966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Medical therapy including diet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optic Nerve Sheath Fenestration
Description: Medical therapy including diet + optic nerve sheath fenestration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventriculoperitoneal CSF Shunting
Description: Medical therapy including diet + ventriculoperitoneal CSF Shunting
Study: NCT02145494

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
Study: NCT01869348

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitor intervention
Description: Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior.
Study: NCT03228563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probioics
Description: CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
Study: NCT00045032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
Study: NCT04622345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSJ-110
Description: ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ophthalmic solution
Study: NCT03162848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE
Description: At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
Study: NCT01964404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Smoked plant with THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Capsule with THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active ingredient
Study: NCT05088408

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resource® Energy Apricot
Description: Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel preparation as usual.
Description: Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy.
Study: NCT01570244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel
Description: multiple doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinylestradiol
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel
Description: multiple doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 201335
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol
Description: multiple doses
Study: NCT02159027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc administered twice daily, dosage based on concomitant medication being taken.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
Study: NCT03623789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous application of tranexamic acid
Description: intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous application of tranexamic acid
Description: intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Floseal hemostatic matrix
Description: application of Floseal® on potential bleeding sites after prosthesis implantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
Study: NCT04610476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone oral 1-5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine oral 2 x 1000 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide oral 20 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast oral 2 x 30 mg/day/1 x 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab s.c. 40 mg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab i.v. 5 mg/kg BW every 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab s.c. 1x 50 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
Study: NCT01911520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex. 4 mg/kg
Description: Patients receive 4 mg/kg Sugammadex.
Study: NCT04610476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks